Aequim Alternative Investments LP - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Aequim Alternative Investments LP ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2022$13,814,000
+4.9%
15,000,000
+7.8%
0.42%
+21.9%
Q1 2022$13,173,000
-2.5%
13,920,0000.0%0.35%
-17.8%
Q4 2021$13,509,000
+4.6%
13,920,0000.0%0.42%
-15.3%
Q3 2021$12,909,000
+18.7%
13,920,000
+21.9%
0.50%
+6.9%
Q2 2021$10,878,000
+256.3%
11,420,000
+280.7%
0.47%
+136.5%
Q1 2021$3,053,000
+7.5%
3,000,0000.0%0.20%
-5.7%
Q4 2020$2,840,0003,000,0000.21%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Context Capital Management, LLC 13,473,000$12,756,0001.74%
Shaolin Capital Management LLC 14,065,000$13,281,0000.93%
ZAZOVE ASSOCIATES LLC 3,773,000$3,584,0000.44%
FARALLON CAPITAL MANAGEMENT LLC 56,695,000$53,806,0000.32%
Baupost Group 30,000,000$28,396,0000.26%
Aequim Alternative Investments LP 3,000,000$2,840,0000.21%
WOLVERINE ASSET MANAGEMENT LLC 24,100,000$22,817,0000.17%
TENOR CAPITAL MANAGEMENT Co., L.P. 5,500,000$5,257,0000.15%
SSI INVESTMENT MANAGEMENT LLC 1,750,000$1,648,0000.12%
GABELLI & Co INVESTMENT ADVISERS, INC. 430,000$406,0000.06%
View complete list of THERAVANCE BIOPHARMA INC shareholders